Krystle Vermes

Two apps designed to assist those with visual impairments can now be used hands-free on wearable devices, such as Apple Watch.

Roche recently launched a point-of-care (POC) test that can help health care professionals accurately diagnose high-risk heart attack patients in just 12 minutes.

The first 3-month treatment for schizophrenia is now commercially available in the United States.

The Advisory Committee on Immunization Practices of the US Centers for Disease Control and Prevention has voted to recommend meningococcal group B vaccination for adolescents and young adults.

Medtronic is globally recalling lots of Covidien Shiley neonatal and pediatric tracheostomy tubes following reports of 12 serious patient injuries.

Valeant has submitted a New Drug Application for an oral formulation of methylnaltrexone bromide to treat opioid-induced constipation in adult patients with chronic noncancer pain.

A battery-powered device that allows blind patients to "see" with their tongues has been cleared by the FDA.

The FDA has issued a Class I recall for the HeartWare Ventricular Assist System (VAS), citing malfunction in the device's electrical connection that could cause serious patient injury or death.

New study results suggest idarucizumab is an effective reversal agent for Boehringer Ingelheim's novel oral anticoagulant (NOAC), dabigatran (Pradaxa).

The FDA has extended its review of Richter and Allergan's atypical antipsychotic, cariprazine, for the treatment of schizophrenia and manic or mixed episodes associated with bipolar disorder.

The FDA has determined the current labeling for the anti-seizure medication ezogabine (Potiga) adequately describes its risks of vision loss and skin discoloration.

Glenmark Pharmaceuticals' levonorgestrel/ethinyl estradiol tablets, a generic version of Teva's Seasonale extended-cycle birth control, have been cleared by the FDA and will begin shipping immediately.

Drug shows improvement in skin thickening with active treatment.

An FDA advisory committee has unanimously recommended approval for GlaxoSmithKline's mepolizumab severe asthma treatment in adults, but not adolescents.

An FDA panel has recommended approval for alirocumab (Praluent) in patients with high cholesterol.

The FDA has granted Breakthrough Therapy Designation to Roche's tocilizumab (Actemra/RoActemra) for the treatment of systemic sclerosis.

Drug is being evaluated for the treatment of patients who received at least 3 prior lines of therapy.

Janssen has submitted a Biologic License Application to the FDA seeking daratumumab's approval in multiple myeloma.

Roche's new tests to detect Clostridium difficile and genital herpes infection have been cleared by the FDA.

Baxter is voluntarily recalling 4 product codes of its Vascu-Guard Peripheral Vascular Patch due to difficulty distinguishing surface textures.

Four separate drug manufacturers have launched generic versions of Shire's Intuniv ADHD treatment for children aged 6 to 17 years.

Keytruda is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands.

The FDA has granted priority review to Merck's pembrolizumab (Keytruda) for the treatment of advanced non-small cell lung cancer (NSCLC).

Therapy is also being evaluated for advanced chronic kidney disease, inherited blood disorders, and liver cirrhosis.

Teva recently launched risedronate sodium tablets, the generic version of Actavis's Actonel bisphosphonate, in 3 dosage strengths.

Merck is seeking FDA approval for its once-daily, single-tablet grazoprevir/elbasvir combination for the treatment of adult patients with chronic hepatitis C virus (HCV) genotypes 1, 4, or 6 infection.

Rare yet serious side effects can transpire from unintentionally injecting soft tissue fillers into blood vessels in the face, the FDA has warned health care professionals.

Treatment blocks signals that may lead to inflammation.

ZS Pharma is requesting FDA approval for sodium zirconium cyclosilicate (ZS-9) for the treatment of hyperkalemia.

Amgen has terminated its co-development and commercialization of brodalumab with AstraZeneca after observing suicidal ideation and behavior in clinical trial participants.